Literature DB >> 17669007

Functionality of the immune system in patients with chronic hepatitis C: trial by superinfections and vaccinations.

Maria G Isaguliants1.   

Abstract

Viral infections, specifically chronic, markedly influence the host response to subsequent infections and vaccinations. Does this apply to chronic hepatitis C (CHC)? The review considers this question with implications for the immune status and functionality of the immune system of a chronically HCV-infected host. The data collected here indicate that CHC may increase the risk of viral superinfections and modify their course by immunocompromising the host. Patients with CHC do not lose the 'memory' of previous infections and vaccinations but, apparently, have problems with building such immunity anew, as illustrated by their impaired response to hepatitis A and B vaccinations. This underlines the necessity of extra protection of CHC patients against blood-borne diseases, hepatitis A, possibly also varicella, influenza, tetanus, and diphtheria - immunity to which, in the Western population, appears to falter. Such immune protection has to be adapted to selective impairments of immune response characteristic to CHC. Some approaches to this are reviewed here and more need to be elaborated. Special attention has to be given to CHC patients who do not respond to common vaccines; further studies in this field are of great interest.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17669007     DOI: 10.1586/14760584.6.4.527

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  2 in total

1.  Association of CMV, HBV, or HCV co-infection with vaccine response in adults with well-controlled HIV infection.

Authors:  S B Troy; A E B Rossheim; J Siik; T D Cunningham; J A Kerry
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

Review 2.  Dendritic cells in hepatitis C infection: can they (help) win the battle?

Authors:  Angela Dolganiuc; Gyongyi Szabo
Journal:  J Gastroenterol       Date:  2011-02-17       Impact factor: 6.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.